Roseville, MN-based Rebiotix says it raised $25 million in a Series B, designed to fund pivotal work on its lead fecal-transplant program for RBX2660. RBX2660 is described as a non-antibiotic treatment under study for recurrent Clostridium difficile (C. diff) infection. There was no word in the release on who provided the cash. Rebiotix was granted fast-track status last year. Release